The use of activated charcoal haemoperfusion can play a complementary role in the substitutive treatment of chronic uraemia. This study reports the preliminary results of a regular combined haemodialysis-haemoperfusion treatment. The effectiveness of this treatment was observed on the subjective symptomatology (anorexia, nausea, asthenia) and on the polyneuropathy evaluated by electrophysiological assessments. The biocompatability of the system proved satisfactory.

Adult↗

PubMedDate not supplied

[Controlled study of the antihypertensive effects of the combination of metoprolol and chlorthalidone].

Explore the source record for details and available documents.

Adult↗

PubMedDate not supplied

[Electromyographic changes induced with oral supplements of carnitine in patients under regular periodical hemodialytic treatment].

Explore the source record for details and available documents.

Action Potentials↗

PubMedDate not supplied

[Spectrophotometric evaluation of N-acetyl-beta-glucosaminidase in urine].

A spectrophotometric method for the assay of N-Acetyl-beta-Glucosaminidase activity in human undiluted urines is described. The application of this method is recommended for its sensitivity (2,6 X 10(-4)M) and its rapid performance, because it represents a good alternative to current methods and essentially to the fluorimetric technique with which it has a significant statistical correlation. Estimates of normal individuals aged between 1-70 years are reported.

Acetylglucosamine↗

PubMedDate not supplied

[Effects of treatment with 1--alpha-hydroxyvitamin D3 in osteodystrophy in uremic patients undergoing periodical hemodialysis].

Explore the source record for details and available documents.

Adult↗

PubMedDate not supplied

N-3 polyunsaturated fatty acid supplementation in chronic progressive renal disease.

Chronic renal failure (CRF) may be accelerated by secondary lipid and immune abnormalities which could be antagonized by polyunsaturated fatty acid (PUFA). We examined 20 CRF patients on conservative treatment, randomized in two groups: G1 consisted of 10 control patients and G2 10 patients supplemented for 12 months with a 3.4 g daily dose of PUFA. In basal conditions and after 12 months the following parameters were checked: creatinine clearance (CCr), daily urinary protein excretion per unit of residual renal function (UProt/CCr), rate of progression of renal insufficiency (delta CCr); triglycerides (TG), total (TC), HDL (HDALC) and LDL (LDLC) cholesterol, apolipoproteins Apo Al, Apo B, lipoprotein(a) Lp(a); lymphocyte subpopulations; spontaneous (c) and stimulated (s) cytokines IL-1 beta, IL-2, tumor necrosis factors TNF-alpha secretion by peripheral mononuclear cells. The groups did not differ in their basal parameters, which did not change in G1 during follow-up. In G2 the following parameters, initially higher than normal significantly decreased after 12 months: TG (2.9 +/- 0.45 to 2.6 +/- 0.3 mmol/l p < 0.005), Apo B (1.40 +/- 0.37 to 1.22 +/- 0.36 g/l, p < 0.05), c TNF-alpha (1008.1 +/- 534.9 to 726.8 +/- 458.7 pg/ml, p < 0.05). Spontaneous (c) IL-1 beta (216.7 +/- 116.2 to 150.5 +/- 107.8 pg/ml, p < 0.05), c IL-2 (124.5 +/- 43.8 to 101.6 +/- 25.8 pg/ml, p < 0.05), and s TNF-alpha (2456.4 +/- 908.3 to 1632.2 +/- 497.1 pg/ml, p < 0.005) also decreased, although already within the normal range at baseline. G2 patients experienced a steady monthly reduction of CCr whereas it rose progressively in G1 (p < 0.05), with a simultaneous increase in UProt/CCr (p < 0.05). PUFA are beneficial on the lipid and immune abnormalities secondary to CRF and may also have a useful effect on the progression of chronic renal damage.

Adult↗